Investigating biomarkers of Staphylococcus aureus bacteremia in patients - School of Pharmacy

The Centers for Disease Control identifies methicillin-resistant S. aureus (MRSA) as a serious health threat with greater than 100,000 invasive infections and 20,000 patient deaths annually in the United States. Despite recent advancements in available treatment options for methicillin-sensitive S.

View of Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans

Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study - The Lancet Infectious Diseases

Infection and the evaluation of biomarkers in obstetrics and gynecology patients with infectious disease: a retrospective observational study from clinical pharmacists' consultation experience, European Journal of Medical Research

Investigating biomarkers of Staphylococcus aureus bacteremia in patients - School of Pharmacy

Phenotyping of Methicillin-Resistant Staphylococcus aureus Using a Ratiometric Sensor Array

Development of Biphenylthiazoles Exhibiting Improved Pharmacokinetics and Potent Activity Against Intracellular Staphylococcus aureus

Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients? - Abstract - Europe PMC

Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections

Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs, Bulletin of the National Research Centre

Pathogens, Free Full-Text